From Care to Cure
Latest Press Releases
Apr 27, 2012
Amsterdam Molecular Therapeutics Reports Full Year Results 2011

Amsterdam, The Netherlands, April 26, 2012 – Amsterdam Molecular Therapeutics (AMT) Holding N.V. (in liquidation) (Euronext: AMT), today reported its results for the year to December 31, 2011.

Key Highlights

  • Glybera® Marketing Authorisation...
Apr 26, 2012
Overview of key transaction elements and timetable with regard to the public-to-private and financing transaction between AMT and uniQure BV

Overview of key transaction elements and timetable with regard to the public-to-private and financing transaction between

Amsterdam Molecular Therapeutics (AMT) Holding N.V.
in liquidation (in liquidatie)
ISIN Code NL0000886968

and

...
Apr 26, 2012
Amsterdam Molecular Therapeutics completes advance distribution of uniQure depositary receipts to AMT shareholders

Amsterdam, The Netherlands – 26 April 2012 – Amsterdam Molecular Therapeutics (AMT) Holding N.V. in liquidation (in liquidatie) (Euronext: AMT), today announces that the advance distribution of uniQure depositary receipts to AMT shareholders was completed today....

Apr 23, 2012
Amsterdam Molecular Therapeutics Receives Further Opinion on Glybera® Marketing Authorisation Application

Amsterdam, The Netherlands – April 23, 2012 – Amsterdam Molecular Therapeutics (AMT) Holding N.V. (in liquidatie) (Euronext: AMT), a leader in the field of human gene therapy, has received notice that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use...

Apr 17, 2012
Amsterdam Molecular Therapeutics reconfirms timetable of principle events of its liquidation process

Amsterdam, The Netherlands – 17 April 2012 – Amsterdam Molecular Therapeutics (AMT) Holding N.V. in liquidation (in liquidatie) (Euronext: AMT), today reconfirms the earlier announced timetable of the principle events of its liquidation process, in view of the...

Apr 6, 2012
Amsterdam Molecular Therapeutics announces completion of disposal of its operations to uniQure B.V. and its dissolution becoming effective

Mar 30, 2012
Amsterdam Molecular Therapeutics Announces Results of Extraordinary General Meeting

Mar 28, 2012
Amsterdam Molecular Therapeutics Publishes Positive Data from Glybera® 14 Week Study

Mar 15, 2012
Proxy for the EGM to be held on 30 March 2012

Mar 15, 2012
Invitation to informational meeting – March 20,2012

Mar 8, 2012
uniQure Q&A

Feb 20, 2012
Amsterdam Molecular Therapeutics Receives Request for Further Information from CHMP on Glybera®

Feb 20, 2012
Invitation to informational meeting – February 23, 2012

Feb 17, 2012
Amsterdam Molecular Therapeutics Business to be Acquired by uniQure BV

Jan 30, 2012
Amsterdam Molecular Therapeutics Announces European Commission Delays Decision on Glybera® Marketing Authorisation And Requests Further Information From the CHMP

Jan 4, 2012
Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy

Dec 30, 2011
Amsterdam Molecular Therapeutics Announces € 2.5 Million Equity Raise

Dec 15, 2011
Amsterdam Molecular Therapeutics Announces Negative Equity Position

Nov 17, 2011
Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011

Nov 16, 2011
Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy

Oct 25, 2011
Amsterdam Molecular Therapeutics Provides Operations Update and Strategic Review of Pipeline

Oct 21, 2011
Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation

Oct 7, 2011
October 7, 2011 - Company visit AMT

Aug 25, 2011
Amsterdam Molecular Therapeutics Reports Half-Year Results 2011

Jul 8, 2011
Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination

Jul 6, 2011
Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer

Jun 29, 2011
Amsterdam Molecular Therapeutics’ Glybera® Significantly Reduces the Risk of Pancreatitis in LPLD Patients

Jun 24, 2011
Amsterdam Molecular Therapeutics Receives Opinion on Glybera Marketing Authorisation Application

May 26, 2011
AMT's Cooperative Research and Development Agreement With NIH to Boost Production Capacity

May 23, 2011
AMT Research Demonstrates AAV Delivery May Be Key Success Factor for Therapeutic Promise of RNAi

May 20, 2011
AMT Presents Data Supporting Role of Chylomicron Clearance as Marker for Glybera Efficacy

May 19, 2011
AMT Provides Business Update for the First Quarter

May 10, 2011
AMT Provides Status Update on Glybera

Mar 23, 2011
AMT Notice of Annual General Meeting

Mar 7, 2011
AMT receives grant from Dutch parents organization for Duchenne Muscular Dystrophy gene therapy

Feb 16, 2011
Amsterdam Molecular Therapeutics Reports Full Year Results 2010

Feb 8, 2011
AMT to Release Full Year 2010 Results on Wednesday February 16, 2011

Jan 31, 2011
AMT Receives €1.1 Million Funding for Acute Intermittent Porphyria Gene Therapy as Part of EU Consortium Grant

Jan 10, 2011
AMT to Supply cGMP Manufacturing to Consortium Led by Institut Pasteur for Development of Sanfilippo B Gene Therapy Product

Jan 6, 2011
AMT Announces that Steven H. Holtzman Has Resigned as a Member of the Supervisory Board Due to Appointment at Biogen Idec

Archived News Releases

2011

2010

2009

2008

2007

Certain statements in this press release are “forward-looking statements” including those that refer to management’s plans and expectations for future operations, prospects and financial condition. Words such as “strategy,” “expects,” “plans,” “anticipates,” “believes,” “will,” “continues,” “estimates,” “intends,” “projects,” “goals,” “targets” and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of AMT only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT’s business. AMT expressly disclaims any intent or obligation to update any forward-looking statements herein except as required by law.